Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release

  • Vesna Sossi
  • Katherine Dinelle
  • Michael Schulzer
  • Edwin Mak
  • Doris J. Doudet
  • Raúl de la Fuente-Fernández
Original Article



Levodopa and dopamine (DA) agonist therapy are two common treatments for Parkinson’s disease (PD). There is controversy about the effects of these treatments on disease progression and imaging markers. Here we used multi-tracer positron emission tomography imaging and a unilateral 6-hydroxydopamine (6-OHDA) rat model of PD to evaluate in vivo the effects of chronic levodopa and pramipexole treatments on measurements of vesicular monoamine transporter type 2 (VMAT2), dopamine transporter (DAT) levels, and on levodopa-induced changes in synaptic DA levels [Δ(DA)].


Twenty-three unilaterally 6-OHDA lesioned rats underwent an 11C-dihydrotetrabenazine (DTBZ, VMAT2 marker), an 11C-methylphenidate (MP, DAT marker), and a double 11C-raclopride (RAC, D2-type receptor marker) scan. They were assigned to three treatment groups: saline (N = 7), pramipexole (N = 8), and levodopa (N = 8). After 4 weeks of treatment, imaging was repeated.


Results showed (1) a significant treatment effect on DTBZ, with pramipexole decreasing DTBZ binding compared to levodopa, (2) significant side and treatment-striatal side interaction effects for MP, indicating that levodopa tends to decrease MP binding compared to pramipexole, and (3) no treatment effect on Δ(DA).


These data indicate that while chronic dopaminergic pharmacological treatment affects DTBZ and MP binding, it does not affect levodopa-induced changes in synaptic DA level.


DAT Dopamine agonist Levodopa 6-OHDA rodent model Parkinson’s disease VMAT2 



This work was supported by CIHR, NSERC, MSFHR and Triumf Life Science.

Conflicts of interest



  1. 1.
    de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5(6):525–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Parkinson’s Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653–61.CrossRefGoogle Scholar
  3. 3.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61(7):1044–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Ahlskog JE. Slowing Parkinson’s disease progression: recent dopamine agonist trials. Neurology 2003;60(3):381–9.PubMedGoogle Scholar
  5. 5.
    Albin RL, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology 2003;60(3):390–4.PubMedGoogle Scholar
  6. 6.
    Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56(11):1559–64.PubMedGoogle Scholar
  7. 7.
    Masuo Y, Pélaprat D, Scherman D, Rostène W. [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neurosci Lett 1990;114:45–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Vander Borght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey K. [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995;68(3):955–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Kemmerer ES, Desmond TJ, Albin RL, Kilbourn MR, Frey KA. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol 2003;183:81–6.CrossRefPubMedGoogle Scholar
  10. 10.
    de la Fuente-Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, et al. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 2003;49(1):20–8.CrossRefGoogle Scholar
  11. 11.
    de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ. Visualizing vesicular dopamine dynamics in Parkinson’s disease. Synapse 2009;63(8):713–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Tong J, Wilson AA, Boileau I, Houle S, Kish SJ. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 2008;62(11):873–6.CrossRefPubMedGoogle Scholar
  13. 13.
    de la Fuente-Fernández R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49(3):298–303.CrossRefPubMedGoogle Scholar
  14. 14.
    Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 2006;99(2):381–92.CrossRefPubMedGoogle Scholar
  15. 15.
    Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006;67(9):1612–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342(20):1484–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson’s disease: a feature inherent to the treatment or the disease? Prog Neurobiol 2009;87(1):1–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Sossi V, Dinelle K, Topping GJ, Holden JE, Doudet D, Schulzer M, et al. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson’s: an in vivo imaging study. J Neurochem 2009;109(1):85–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic; 1998.Google Scholar
  20. 20.
    Breese GR, Traylor TD. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol 1971;42:88–99.PubMedGoogle Scholar
  21. 21.
    Kelly PH, Iversen SD. Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 1976;40:45–56.CrossRefPubMedGoogle Scholar
  22. 22.
    Whishaw IQ, Gorny B, Tran-Nguyen LTL, Casteñeda E, Miklyaeva EI, Pellis SM. Making two movements at once: impairments of movement, posture, and their integration underlie the adult skilled reaching deficit of neonatally dopamine-depleted rats. Behav Brain Res 1994;61:65–77.CrossRefPubMedGoogle Scholar
  23. 23.
    Chernoloz O, El Mansari M, Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009;34(3):651–61.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim JS, Lee JS, Im KC, Kim SJ, Kim SY, Lee DS, et al. Performance measurement of the microPET focus 120 scanner. J Nucl Med 2007;48:1527–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Sossi V, Holden JE, Topping GJ, Camborde ML, Kornelsen R, McCormick S, et al. In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood Flow Metab 2007;27(7):1407–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Schiffer WK, Alexoff DL, Shea C, Logan J, Dewey SL. Development of a simultaneous PET/microdialysis method to identify the optimal dose of 11C-raclopride for small animal imaging. J Neurosci Methods 2005;144(1):25–34.CrossRefPubMedGoogle Scholar
  27. 27.
    Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997;6(4):279–87.CrossRefPubMedGoogle Scholar
  28. 28.
    Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Zigmond MJ, Stricker EM, Berger TW. Parkinsonism: insights from animal models utilizing neurotoxic agents. In: Coyle JY, editor. Animal models of dementia. New York: Alan R. Liss; 1987. p. 1–38.Google Scholar
  30. 30.
    Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27(9):1533–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol 2000;47(4):493–503.CrossRefPubMedGoogle Scholar
  32. 32.
    Truong JG, Rau KS, Hanson GR, Fleckenstein AE. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson’s neurodegeneration. Eur J Pharmacol 2003;474(2-3):223–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996;312(1):35–44.CrossRefPubMedGoogle Scholar
  34. 34.
    Rodriguez M, Gonzalez S, Morales I, Sabate M, Gonzalez-Hernandez T, Gonzalez-Mora JL. Nigrostriatal cell firing action on the dopamine transporter. Eur J Neurosci 2007;25:2755–65.CrossRefPubMedGoogle Scholar
  35. 35.
    Sossi V, de la Fuente-Fernández R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson’s disease: a positron emission tomography study. Ann Neurol 2007;62(5):468–74.CrossRefPubMedGoogle Scholar
  36. 36.
    Wu Q, Reith ME, Walker QD, Kuhn CM, Carroll FI, Garris PA. Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: an in vivo voltammetric study. J Neurosci 2002;22:6272–81.PubMedGoogle Scholar
  37. 37.
    Smits SM, Ponnio T, Conneely OM, Burbach JP, Smidt MP. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur J Neurosci 2003;18:1731–8.CrossRefPubMedGoogle Scholar
  38. 38.
    de la Fuente-Fernández R, Lim AS, Sossi V, Holden JE, Caine DB, Ruth TJ, et al. Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab 2001;21:1151–9.CrossRefGoogle Scholar
  39. 39.
    Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 1997;94:3363–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006;5:25–43.CrossRefPubMedGoogle Scholar
  41. 41.
    Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett 2005;377:106–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Chiasson K, Daoust B, Levesque D, Martinoli MG. Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells. Neurotox Res 2006;10:31–42.CrossRefPubMedGoogle Scholar
  43. 43.
    Lundblad M, af Bjerkén S, Cenci MA, Pomerleau F, Gerhardt GA, Strömberg I. Chronic intermittent L-DOPA treatment induces changes in dopamine release. J Neurochem 2009;108(4):998–1008.CrossRefPubMedGoogle Scholar
  44. 44.
    Murer MG, Dziewczapolski G, Menalled LB, García MC, Agid Y, Gershanik O, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43(5):561–75.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Vesna Sossi
    • 1
    • 2
  • Katherine Dinelle
    • 1
  • Michael Schulzer
    • 2
  • Edwin Mak
    • 2
  • Doris J. Doudet
    • 1
  • Raúl de la Fuente-Fernández
    • 1
    • 2
  1. 1.University of British ColumbiaVancouverCanada
  2. 2.Department of Physics and AstronomyVancouverCanada

Personalised recommendations